Skip to content
Search

Latest Stories

PSNC share tips for pharmacy contractors to reduce HRT SSP endorsement errors

The Pharmaceutical Services Negotiating Committee (PSNC) has advised the pharmacy contractors to check that their PMR systems supports correct and complete SSP endorsement.


Several tips has been shared by the PSNC with pharmacy contractors after NHSBSA received several electronic EPS SSP claims which did not meet the requirements for a valid SSP between 1 April 2022 and 31 May 2022.

PSNC has been working with NHS Business Services Authority (NHSBSA) to understand whether claims for HRT SSPs are being submitted correctly and in accordance with the specific supporting guidance for each SSP.

The reasons for incorrect/invalid SSP claims were due to:

  1. Reduced quantity not endorsed – for SSPs that require a reduced quantity to be endorsed, often the endorsed quantity matched the prescribed quantity. Majority of invalid SSP claims were due to this reason.
  2. Incorrect item endorsed – for SSPs that require substitution to an alternative product, the endorsed item was almost always the same as original prescribed item.
  3. Claims made against items without an active SSP – SSP endorsed against items for which a valid SSP did not exist.
  4. Claims for supplies made in accordance with an expired SSP:

    A. No active SSP in place at the time of supply – i.e., SSP claimed for items on prescriptions issued after SSP expired.

    B. Alternative item correctly supplied during the period of SSP validity, but Dispense Notification message submitted after the period of SSP validity.

    C. Alternative item correctly supplied during the period of SSP validity and the Dispense Notification message submitted during the period of SSP validity but the EREM or Claim Notification message submitted after the 3-month claiming window.5. Invalid or incorrect SSP reference number endorsed – For example SSP 000, SSP (missing reference number), SSP 028 (incorrect number), SSP 28 (two instead of three digits).

“For any invalid SSP claims, contractors will continue to receive the usual dispensing fee but will not receive any SSP fee (£5.35). Reimbursement for invalid SSP claims will also be in accordance with the prescribed product rather than the alternative product or quantity supplied in accordance with an SSP,” said PSNC.

“To ensure correct payments for SSP claims are received, contractors should follow the endorsement requirements outlined in the specific supporting guidance for each SSP,” suggested PSNC. “Contractors are strongly advised to check that their PMR systems supports correct and complete SSP endorsements. If there is any doubt on the correct use of the PMR system SSP functionality, contractors should contact their system supplier for further guidance.  Any suggestions about how system usability and functionality could be improved should also be fed back to the system supplier.”

PSNC’s Dispensing & Supply team have created easy to use flow charts to assist pharmacists in selecting the correct SSP for HRT medicines. These charts also remind contractors of the correct SSP endorsement requirements (with examples) and charge status to apply to the electronic messages before SSP claims are submitted for payment to the NHSBSA.

More For You

Public Policy Projects calls for better use of community pharmacy skill mix to improve medicines adherence
Non-adherence to medicines remains a critical issue, with an estimated 30 to 50 per cent of medicines for long-term conditions not taken as prescribed. (gettyimages)

Leverage pharmacy skill mix to improve medicines adherence - report suggests

The report also suggested expanding the community pharmacy contractual framework to enable community pharmacy to deliver medicines reviews

Pharmacy technicians and assistants should be enabled to talk to patients about their medications to improve medicines adherence, a new report has recommended.

Keep ReadingShow less
Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Kinnock confirms that an announcement on the 2025/26 GP contract would be made before April 2025

The 2025/26 pharmacy contract consultation will include a review of the medicine margin and reimbursement arrangements, health and care minister Stephen Kinnock has confirmed.

Keep ReadingShow less
NHS expands pharmacogenomics trial to enhance personalised medicine
The NHS is poised to take a bold step towards personalised medicine (gettyimages)

Personalised medicine: NHS expands pharmacogenomics trial across England

With this study, the NHS aims to address barriers to the national implementation of pharmacogenomics, making personalised medicine to become standard practice

A national pharmacogenomics research study is making significant progress towards adopting personalised medicine within the NHS.

Keep ReadingShow less
Integrating clinical pharmacists into general practice significantly reduced medicine costs, opioid prescriptions, and anxiolytic use
The growing presence of clinical pharmacists in GP practices is driving improvements in in quality of prescribing and patient safety (gettyimages)

Clinical pharmacists in GP practices improve prescribing quality, patient safety

Integrating clinical pharmacists into general practice significantly reduced medicine costs, opioid prescriptions, and anxiolytic use

The growing presence of clinical pharmacists in GP practices is driving improvements in in quality of prescribing and patient safety in primary care settings, a new study has revealed.

Keep ReadingShow less
India aims to become a top five pharma exporter by 2047
India is the world’s largest supplier of generic medicines (gettyimages)

India’s pharma exports expected to cross £280 billion by 2047

India aims to become a top five pharma exporter by expanding into specialty generics, biosimilars and innovative products

India’s pharmaceutical exports are projected to grow from $27 billion (£21.73 billion) in 2023 to $65 billion (£ 52.31 billion) by 2030, with the potential to reach an estimated $350 billion (£281.72 billion) by 2047, according to a new industry report.

Keep ReadingShow less